News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Applied Nanoscience Comments on Trading Activity and Share Volume


4/28/2009 11:05:05 AM

CARLSBAD, CA--(Marketwire - April 28, 2009) -

Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration development company, today commented that the unusually heavy share volume and active trading in its stock yesterday is likely tied to the current swine flu outbreak. More specifically, the potential applicability of the company's core technology, NanoFense™, a proprietary antimicrobial nanoparticle formulation developed by ANI to coat or impregnate virtually any air filter media could be viewed as an advantageous product enhancement by air filtration companies.

ANI's NanoFense formulation has already been validated at well-known BSL-3 laboratories to be highly effective against the avian influenza simulant strain H9N2, the Human Influenza A virus as well as Haemophilus influenzae (H-flu). According to an independent virologist familiar with the technology and past testing, it is highly probable that the NanoFense formulation will be similarly effective against the current swine influenza strain A/H1N1.

About ANI

ANI is a marketer and developer of innovative, high performance nanotechnology-based filtration products to customers worldwide and is the owner of NEFT™ (Nanoparticle - Enhanced - Filtration - Technology), a broad platform with significant application potential in consumer market segments.

For further information about Applied Nanoscience Inc., please visit: www.appliednanoscience.com

Safe Harbor Statement

This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. ANI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the company could differ significantly from such forward-looking statements.


Contact:
Philippe Niemetz
800-477-7570 or 212-344-6464
p.niemetz@panconsultants.com
Investor Relations
PAN Consultants Ltd.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES